The amount of accrued to related party amount.

No definition available.

Name:	abp_AccruedToAmount
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Annual sales milestone payments.

+ References

No definition available.

+ Details

Name:	abp_AnnualSalesMilestonePayments
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represent the clinical development milestones.

+ References

No definition available.

+ Details

Name:	abp_ClinicalDevelopmentMilestones
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represent the commercial sales.

+ References

No definition available.

+ Details

Name:	abp_CommercialSales
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Derecognize Liability

+ References

No definition available.

+ Details

Name:	abp_DerecognizeLiability
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Development milestones.

+ References

No definition available.

+ Details

Name:	abp_DevelopmentMilestones
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Represents milestone payment based on net sales

+ References

No definition available.

+ Details

Name:	abp_MilestonePaymentOnNetSales
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represent the milestone payment.

+ References

No definition available.

+ Details

Name:	abp_MilestonePayments
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Milestone payments commercial milestones.

+ References

No definition available.

+ Details

Name:	abp_MilestonePaymentsCommercialMilestones
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represents milestone payments upon achieving research and development and commercialization events.

+ References

No definition available.

+ Details

Name:	abp_MilestonePaymentsUponAchievingRDAndCommercializationEvents
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Net profits from licensed product sales.

+ References

No definition available.

+ Details

Name:	abp_NetProfitsFromLicensedProductSales
Namespace Prefix:	abp_
Data Type:	dtr:percentItemType
Balance Type:	na
Period Type:	duration

- Definition

related to the patent costs reimbursements.

+ References

No definition available.

+ Details

Name:	abp_PatentCostsReimbursements
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The company is liable for extension royalties.

+ References

No definition available.

+ Details

Name:	abp_PaymentForExtensionRoyalities
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of payment of development milestones.

+ References

No definition available.

+ Details

Name:	abp_PaymentOfDevelopmentMilestones
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

Represent the regulatory events.

+ References

No definition available.

+ Details

Name:	abp_RegulatoryEvents
Namespace Prefix:	abp_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 942
-SubTopic 210
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-03(15)(5))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147478546/942-210-S99-1

+ Details

Name:	us-gaap_AccruedLiabilitiesCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(20))
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1

Reference 2: http://www.xbrl.org/2003/role/exampleRef
-Topic 210
-SubTopic 10
-Name Accounting Standards Codification
-Section 45
-Paragraph 8
-Subparagraph (c)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147483467/210-10-45-8

+ Details

Name:	us-gaap_AccruedRoyaltiesCurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Carrying value as of the balance sheet date of obligations incurred through that date and payable for royalties.

+ References

+ Details

Name:	us-gaap_AccruedRoyaltiesCurrentAndNoncurrent
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.

+ References

Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Topic 808
-SubTopic 10
-Name Accounting Standards Codification
-Section 50
-Paragraph 1
-Subparagraph (d)
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147479402/808-10-50-1

+ Details

Name:	us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The amount of cash paid for royalties during the current period.

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Name Accounting Standards Codification
-Section 45
-Paragraph 25
-Subparagraph (g)
-SubTopic 10
-Topic 230
-Publisher FASB
-URI https://asc.fasb.org/1943274/2147482740/230-10-45-25

+ Details

Name:	us-gaap_PaymentsForRoyalties
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_IncomeStatementLocationAxis=us-gaap_ResearchAndDevelopmentExpenseMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=abp_MedImmuneLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=abp_NCILicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=abp_MSKLicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=abp_VAZYMELicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ExtinguishmentOfDebtAxis=us-gaap_AccountsPayableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ExtinguishmentOfDebtAxis=abp_OtherAccruedExpensesAndAccountsPayableMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_ExtinguishmentOfDebtAxis=abp_OtherAccruedExpensesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_CounterpartyNameAxis=abp_VAZYMEMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MinimumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	srt_RangeAxis=srt_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Commitments under Research and Collaboration Agreements (Details) - USD ($) $ in Thousands	1 Months Ended		3 Months Ended	12 Months Ended
	Mar. 31, 2025	Mar. 31, 2022	Dec. 31, 2025	Dec. 31, 2025	Dec. 31, 2024
Commitments under Research and Collaboration Agreements [Line Items]
Clinical development milestones				$ 14,000
Regulatory events				80,000
Commercial sales				150,000
Milestone payments commercial milestones				12,000
Accrued royalties			$ 52	52	$ 25
Extension royalties		$ 225
Accrued extension royalties			200	200	200
Development milestones				32,500
Annual sales milestone payments				$ 50,000
Net profits from licensed product sales				50.00%
Payment of development milestones	$ 3,300
Accrued amount					3,300
Derecognize liability			3,300
Accrued liabilities			325	$ 325	325
Research and Development Expense [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Milestone payments				70,000
Royalties amount				25	25
MedImmune License Agreement [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Milestone payments				244,000
NCI License Agreement [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Milestone payments				3,995
Royalties amount				25
MSK License Agreement [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Milestone payment upon achieving			10,500
Milestone payment on net sales			30,000
VAZYME License Agreement [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Milestone payments				200
Accrued liabilities			200	200	200
Accounts Payable [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Milestone payments			790
Accounts Payable [Member] \| MSK License Agreement [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Milestone payments					790
Other Accrued Expenses and Accounts Payable [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Patent costs reimbursements				273	273
Other Accrued Expenses [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Patent costs reimbursements				169	$ 169
VAZYME [Member] \| VAZYME License Agreement [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Milestone payments				$ 11,100
Minimum [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Royalties amount			20
Maximum [Member]
Commitments under Research and Collaboration Agreements [Line Items]
Royalties amount			$ 30